Lipoprotein lipase (LPL) is essential for the hydrolysis and distribution of triglyceride-rich lipoprotein-associated fatty acids among extrahepatic tissues. Additionally, the enzyme facilitates several non-lipolysis associated functions including the cellular uptake of whole lipoprotein particles and lipophilic vitamins. The tissue-speci®c variations of LPL expression have been implicated in the pathogenesis of various lipid disorders, obesity and atherosclerosis. Transgenic technology provided the means to study the physiological response to the overexpression or absence of the enzyme in adipose tissue, muscle and macrophages. The effects of varying LPL expression in adipose tissue and muscle are summarized in this article.
Introduction
Fat accumulation in adipose tissue (AT) largely depends on the ef®cient uptake of fatty acids from the circulation. Since the majority of fatty acids in plasma are present in esteri®ed form as lipoprotein associated triglycerides (TG), hydrolysis is a mandatory initial step for the tissue absorption of free fatty acids (FFA). In peripheral tissues, such as AT, the rate-limiting step for TG catabolism is catalyzed by lipoprotein lipase (LPL), an enzyme which is bound to glucosaminoglycans at the luminal side of the capillary endothelium. The activity of LPL in AT relative to its expression in other tissues, such as skeletal muscle (SM) and cardiac muscle (CM), determines the in¯ux of FFA and, possibly, the amount of fat deposited. LPL is therefore viewed as a`gate keeping' enzyme for the entry and reesteri®cation of FFA in AT. 1 According to this hypothesis, decreased LPL activity in AT could reduce FFA uptake and lipid accumulation. Alternatively, overexpression of LPL in muscle might be associated with the redirection of nutrient fats from AT to muscle (`substrate steal'), again preventing FFA uptake in adipocytes. It is likely, therefore, that LPL and its tissue-speci®c regulation are centrally involved in the pathogenesis of obesity. In addition, LPL plays a key role in the metabolism of lipoproteins, which makes it an important factor in vascular disease as well. The advent of transgenic technology provided the means to directly modulate LPL expression levels in mice in a tissuedependent manner and study the tissue-speci®c role of the enzyme. This article will summarize some of the ®ndings that emerged from these studies.
Disruption of the mouse LPL gene
Familial LPL de®ciency is a rare autosomal recessive disorder in humans, characterized by a massive accumulation of chylomicrons (type I hyperlipoproteinemia). 2 Homozygous patients, when not kept under strict dietary control, exhibit plasma triglycerides above 3000 mgadl, essentially lack HDL and suffer from recurring episodes of pancreatitis. To date more than 80 different mutations within the LPL structural gene are known to cause the disorder. Generally, LPL de®ciency is not associated with an increased incidence of atherosclerosis; however, in some families an increased prevalence of heart disease has been reported. 3 This observation indicated that mutationspeci®c variations exist with regard to atherosclerosis susceptibility. Interestingly, patients with LPL de®-ciency have normal amounts of AT, suggesting alternative, LPL-independent pathways to accumulate TG in adipocytes. 4 Several years ago two laboratories reported independently the generation of LPL knock-out mice. 5, 6 Homozygous LPL-de®cient animals also developed severe hypertriglyceridemia, hypercholesterolemia and low HDL, but in contrast to humans all knock-out animals died within 30 h after birth. This phenotype was similar to the one observed in the well-studied cldacld-mouse, namely severe hypertriglyceridemia and post-natal death as a result of the de®ciency of enzymatically active LPL and hepatic lipase. 7 Both mouse models, cldacld and LPL knock-out, suggested that LPL-de®cient mice, in contrast to humans, cannot tolerate the massive amount of TG that accumulates in the blood as soon as the newborn animals begin to suckle. Although the exact cause of death has not been elucidated, it has been speculated that the excessive blood-lipid content could clog the lung capillaries and interfere with a functional gas exchange, resulting in alveolar dysfunction and cyanosis. 5 Hypoglycemia was proposed as an alternative cause of death by Merkel et al, 8 when the authors observed that newborn LPL knock-out mice had unusually low blood glucose levels. Recent experiments in our laboratory utilizing the transient post-natal adenovirus mediated expression of LPL has enabled us to rescue LPL knock-out mice during the suckling period and generate adult, LPL-de®cient animals to an age well over 12 months. These mice exhibited increased TG levels, extremely low HDL concentrations and increased FFA and ketones in plasma when kept on a chow diet. Gross morphological examination revealed the presence of roughly normal amounts of AT.
Tissue-speci®c overexpression of LPL

Skeletal muscle
LPL overexpression in skeletal muscle (SM) was achieved by fusing an LPL minigene to the promoter of the mouse muscle creatine kinase gene. 9 ± 11 A 5-fold overexpression of LPL in SM caused a marked decrease in TG rich lipoproteins, decreased HDL levels, and low plasma FFA concentrations. 9, 10 The work by Jensen et al 10 provided convincing evidence that low-level overexpression of LPL in SM can decrease a diet-induced weight gain in agreement with the`substrate steal' concept. Higher levels of LPL overexpression, however, resulted in the proliferation of mitochondria and peroxisomes in SM, which eventually led to a severe myopathy and premature death. 9 These experiments indicated that TG hydrolysis by SM-LPL and the subsequent uptake of the FFA by muscle tissue is very ef®cient. The apparently unrestricted FFA uptake that leads to myopathy suggested that LPL is the major determinant for FFA uptake in muscle and that no additional regulatory mechanism exists to prevent the ultimately lethal FFA accumulation in SM.
Muscle-speci®c LPL overexpression in transgenic mice also enabled an investigation of the role of LPL in the uptake of apolar lipids (cholesteryl esters) and lipophilic vitamins (vitamin E). 12,13 A clear linear relationship was observed between LPL activity in SM and the uptake of a-tocopherol, providing in vivo evidence for the involvement of LPL in cellular vitamin E uptake.
Cardiac muscle LPL overexpression in cardiac muscle (CM) was achieved by the fusion of the LPL minigene with promoter sequences from the mouse LPL gene. 14 Eight kilobases (kb) of 5 0¯a nking region of the mouse LPL gene were suf®cient for CM-speci®c LPL expression, but were unable to drive transgene transcription in SM or AT. Even moderate levels of CM-speci®c LPL overexpression had a pronounced effect on VLDL catabolism and plasma TG levels, indicating a particularly powerful role of CM-LPL in the catabolism of TG-rich lipoproteins.
Liver
Liver-speci®c overexpression of LPL was achieved by the fusion of the minigene with the promoter for apolipoprotein AI. 8 Despite a 4 ± 9-fold overexpression of the human enzyme in the liver, the effects on plasma lipids and liver lipid accumulation were quite moderate. Interestingly, however, these animals exhibited a marked increase in plasma ketones in response to increased FFA uptake in the liver.
Tissue-speci®c LPL transgene expression on an LPL knock-out background
Crossbreeding of tissue-speci®c LPL overexpressing transgenic animals with heterozygous LPL knock-out animals resulted in mice that expressed only the transgene but not the endogenous LPL gene. Depending on the tissue of transgene expression, these animals produced LPL activity only in SM, CM or liver but lacked the enzyme in all other tissues, including AT and macrophages. Independent of the site of LPL expression, all mouse lines were rescued from the lethal hypertriglyceridemia present in LPL knock-out mice. This ®nding indicated that LPL expression in any one of these tissues is adequate for survival. Conversely, complete loss of LPL expression in any of these tissues does not cause lethality. In fact, all of the above mouse lines remain grossly healthy and have a normal life expectancy. Additionally, LPL activity measurements in various tissues of thesè single tissue' expressors demonstrated that LPL predominantly remains in the tissue where it was originally synthesized. No evidence was obtained for the translocation of a considerable amount of enzymatically active enzyme from the site of synthesis to other tissues.
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LPL-de®cient AT
The lack of LPL in AT of mice expressing LPL exclusively in SM or CM 14 ± 16 did not cause a massive loss of AT mass or altered body mass when the animals were kept on a chow diet. However, leptinde®cient animals were found to be much more resistant to obesity when they lacked LPL in AT. 16 The drastically reduced content of polyunsaturated fatty acids (PUFA) in the AT lipid moiety of AT-LPL de®cient mice suggested, however, that the lack of import of exogenous FFA was replaced by endogenous FFA and TG synthesis. Recent efforts in this laboratory to analyze the activity of glycolytic and lipogenic enzymes support this hypothesis. Additionally, other mechanisms are conceivable that could alleviate LPL de®ciency and facilitate lipid synthesis in AT under normal dietary conditions. These include the increased receptor-mediated uptake of whole lipoprotein particles (eg VLDL receptor) as well as the action of alternative lipases such as the recently discovered endothelial derived lipase. 17, 18 LPL-de®cient SM and AT
The loss of 80% of total body LPL due to the LPL de®ciency in AT and SM in mice expressing LPL exclusively in CM did not cause hypertriglyceridemia or decreased HDL cholesterol levels when kept on normal chow diet.
14 This unexpected result again illustrates the powerful role of CM-LPL in the clearance of plasma TG and suggests that the site of LPL expression is more important than the overall amount of LPL for a functional metabolism of lipids and lipoproteins. Furthermore, the lack of LPL in SM in mice that expressed LPL exclusively in the heart did not cause marked morphological or histopathological changes in either muscle type, indicating that the alternative use of glucose and nonesteri®ed fatty acids (derived from adipose tissue lipolysis) as energy substrate was suf®cient to sustain normal energy metabolism. The effects of decreased PUFA content on membrane properties and function, or prostaglandin metabolism, remain to be investigated.
LPL-de®cient macrophages
The role of macrophage LPL in the formation of foam cells and atherosclerotic lesions is not well understood and has received signi®cant attention recently. In the absence of LPL, the ability of macrophages to bind and take up TG-rich lipoproteins (VLDL) or modi®ed lipoproteins (oxidized LDL) is strongly reduced. 19 Importantly, bone marrow transplantation experiments revealed that the absence of LPL in monocytesamacrophages markedly reduces the susceptibility of C57B16 mice to develop atherosclerotic lesions when fed a high cholesterol diet. 20, 21 In contrast to the bene®cial role of high LPL activities in peripheral tissues to ensure low TG and high HDL cholsterol levels, thereby decreasing the atherosclerotic risk, high LPL activities in macrophages of mice appear to induce lipid accumulation, foam cell formation and atherosclerosis susceptibility.
Future directions
The initial experiments using induced mutant mouse lines have clearly demonstrated that variations in the tissue speci®c expression pattern of LPL can affect the lipid transport system, the distribution of energy substrate and the pathophysiology of obesity and atherosclerosis. In fact, the site of enzyme expression might be more important than the undifferentiated, additive activity that is generally measured in postheparin plasma. To strengthen the evidence provided from these initial observations, future work will have to address the following topics.
1. It will be necessary to generate and study conditional knock-out mice by utilizing the cre-loxP technology. This will permit more physiologically relevant modulations of LPL activities in single tissues that resemble more closely the in vivo situation of varying tissue-speci®c LPL activities in response to nutritional and hormonal changes compared to current animal models. Additionally, to date no transgenic mouse lines have been reported which overexpress LPL in AT. It will be interesting to observe whether a marked overexpression of the enzyme in adipocytes can cause obesity in mice or whether alternative mechanisms can prevent fat accumulation. 2. It will be important to elucidate the metabolic changes in adipocytes that lack LPL. Preliminary experiments indicate that the decreased FFA import under this condition can initiate a whole spectrum of metabolic adaptations which allow the fat cell to continue to produce considerable amounts of fat. These alternative pathways of lipogenesis need to be characterized with regard to their initiation and regulation. 3. The gene regions that regulate tissue-speci®c transcription of LPL and the corresponding transcription factors will have to be characterized in more detail. Presently, insuf®cient information is available describing the major enhancer regions that control LPL expression in AT, SM, CM and macrophages. Yet, only a detailed understanding of the transcriptional mechanisms that govern LPL expression in distinct tissues will enable the development of drugs for potential pharmacological interventions.
